General Information of DTT (ID: TTIS03D)

DTT Name Alpha-galactosidase A (GLA) DTT Info
Gene Name GLA

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
2 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Migalastat DMFIQ2H Fabry disease 5C56.01 Approved [1]
Pegunigalsidase alfa DMOUW65 Fabry disease 5C56.01 Approved [2]
------------------------------------------------------------------------------------
4 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
4D-310 DMNG59Y Fabry disease 5C56.01 Phase 1/2 [3]
AVR-RD-01 DMC1XHK Fabry disease 5C56.01 Phase 1/2 [4]
isaralgagene civaparvovec DM5SSPZ Fabry disease 5C56.01 Phase 1/2 [5]
ST-920 DMOJIPG Fabry disease 5C56.01 Phase 1/2 [6]
------------------------------------------------------------------------------------
7 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
(+)-5-deoxyadeenophorine DMF8C50 Discovery agent N.A. Investigative [7]
2,5-dideoxy-2,5-imino-D-altritol DMI1O54 Discovery agent N.A. Investigative [8]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [9]
Beta-1-C-butenyl-1-deoxygalactonojirimycin DM6GTBC Discovery agent N.A. Investigative [8]
Beta-1-C-Butyl-1-deoxygalactonojirimycin DMMKDEZ Discovery agent N.A. Investigative [8]
CALYSTEGINE B2 DMMBA70 Discovery agent N.A. Investigative [10]
Fucose DMAHMSV N. A. N. A. Investigative [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Investigative Drug(s)
Molecule Interaction Atlas

References

1 AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45.
2 Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67.
3 Clinical pipeline report, company report or official report of 4D Molecular Therapeutics
4 Clinical pipeline report, company report or official report of Avrobio.
5 ClinicalTrials.gov (NCT04046224) A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR). U.S.National Institutes of Health.
6 AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Mol Ther Methods Clin Dev. 2020 Jul 9;18:607-619.
7 Flexible synthesis and biological evaluation of novel 5-deoxyadenophorine analogues. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3262-7.
8 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.
9 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
10 Identification of the glycosidase inhibitors swainsonine and calystegine B2 in Weir vine (Ipomoea sp. Q6 [aff. calobra]) and correlation with toxicity. J Nat Prod. 1995 Jun;58(6):878-86.